Context Therapeutics CNTX
Context Therapeutics reported a net loss of $7.62 million
Context Therapeutics (CNTX) filed a 10-Q with the SEC on Nov 10, 2026, 4:12 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001628280-26-072730
- Net loss of $7.62 million for the three months ended Sep 30, 2026
- Diluted EPS of -$0.08 for the three months ended Sep 30, 2026
- Cash and equivalents of $34.41 million as of Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
Going-concern warning is new
“As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.”
First warning: the prior 10-Q (filed Aug 5, 2026) had no going-concern warning. Prior report Prior on EDGAR
Quoted from the filing.
What changed since last quarter
1 new risk factor
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | −$7.96M | −$14.97M | +47% |
| Net income | −$7.62M | −$14.56M | +48% |
| Operating cash flow | −$6.58M | −$7.02M | +6.3% |
| Cash | $34.41M | $42.99M | −20% |
New risk factors (1)
- There is substantial doubt regarding our ability to continue as a going concern. We will require additional capital to fund our operations, and if we are unable to obtain sufficient capital, we may need to curtail and reduce our operations and costs and modify our business strategy. +8 more paragraphs